share_log

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

Bausch Health Announces 2024 Annual Meeting of Shareholder Results

Bausch Health 公佈 2024 年年度股東大會業績
Bausch Health ·  05/15 12:00

LAVAL, Quebec, May 15, 2024– Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced the results of its 2024 annual meeting of shareholders.

魁北克省拉瓦爾,2024年5月15日——鮑什健康公司(紐約證券交易所/多倫多證券交易所代碼:BHC)今天公佈了其2024年年度股東大會的結果。

Annual Meeting Results

年會結果

The 10 directors nominated at the Company's 2024 annual meeting of shareholders held on May 14, 2024, were elected by a vote of the shareholders. The detailed results of the vote for the election of directors are set out below:

在2024年5月14日舉行的公司2024年年度股東大會上提名的10名董事由股東投票選出。董事選舉投票的詳細結果載列如下:

Name

For

Withheld

Broker Non-Votes

Thomas J. Appio

181,373,219

10,918,741

70,931,303

Christian A. Garcia

181,143,285

11,148,675

70,931,303

Brett M. Icahn

170,144,670

22,147,290

70,931,303

Sarah B. Kavanagh

180,316,464

11,975,496

70,931,303

Frank D. Lee

173,147,642

19,144,318

70,931,303

Steven D. Miller

177,700,669

14,591,291

70,931,303

Dr. Richard C. Mulligan

175,256,854

17,035,106

70,931,303

John A. Paulson

179,422,691

12,869,269

70,931,303

Robert N. Power

173,228,670

19,063,290

70,931,303

Amy B. Wechsler, M.D.

181,626,477

10,665,483

70,931,303

姓名

對於

扣留

經紀人非投票

托馬斯·阿皮奧

181,373,219

10,918,741

70,931,303

克里斯蒂安 A. 加西亞

181,143,285

11,148,675

70,931,303

佈雷特·M·伊坎恩

170,144,670

22,147,290

70,931,303

莎拉·B·卡瓦納

180,316,464

11,975,496

70,931,303

弗蘭克·D·李

173,147,642

19,144,318

70,931,303

史蒂芬·米勒

177,700,669

14,591,291

70,931,303

理查德·穆里根博士

175,256,854

17,035,106

70,931,303

約翰·A·保爾森

179,422,691

12,869,269

70,931,303

羅伯特 ·N· 鮑爾

173,228,670

19,063,290

70,931,303

艾米 ·B· 韋克斯勒,醫學博士

181,626,477

10,665,483

70,931,303

At the annual meeting of shareholders, shareholders also approved, in a non-binding advisory vote, the compensation of the Company's named executive officers, an amendment to the Company's 2014 Omnibus Incentive Plan to increase the number of common shares authorized for issuance thereunder, and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2025 annual meeting of shareholders.

在年度股東大會上,股東們還在不具約束力的諮詢投票中批准了公司指定執行官的薪酬,批准了公司2014年綜合激勵計劃的修正案,以增加根據該計劃授權發行的普通股數量,並任命普華永道會計師事務所爲公司的獨立註冊會計師事務所,直到公司2025年年度股東大會閉幕。

For the purposes of Toronto Stock Exchange (TSX) approval with respect to the Plan, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as the NYSE.

爲了獲得多倫多證券交易所(TSX)對該計劃的批准,該公司依據《多倫多證券交易所公司手冊》第602.1條中規定的豁免,該條款規定,多倫多證券交易所不會將其標準適用於涉及認可交易所(例如紐約證券交易所)合格上市發行人的某些交易。

The final vote tabulation on all matters voted on at the meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K, and such report will be made available on the Company's SEDAR profile and on the Company's website at www.bauschhealth.com.

會議上表決的所有事項的最終投票表將根據8-K表的最新報告向美國證券交易委員會報告,該報告將在公司的SEDAR簡介和公司網站上公佈,網址爲 www.bauschhealth.com

About Bausch Health

關於 Bausch 健康

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership of Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.

Bausch Health Companies Inc.(紐約證券交易所/多倫多證券交易所代碼:BHC)是一家全球多元化製藥公司,通過不懈努力提供更好的醫療保健成果,豐富生活。通過我們對Bausch + Lomb Corporation的控股權,我們開發、製造和銷售一系列產品,主要涉及胃腸病學、肝病學、神經病學、皮膚科、國際藥品和眼部健康。我們的目標是成爲一家全球綜合醫療保健公司,受到患者、HCP、員工和投資者的信任和重視。欲了解更多信息,請訪問 www.bauschhealth.com 然後通過以下方式聯繫我們 領英

Investor Contact: Media Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll-free)
Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785
投資者聯繫人: 媒體聯繫人:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642(免費電話)
凱文威金斯
corporate.communications@bauschhealth.com
(908) 541-3785

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論